Monthly Archives: February 2013

Dummit’s Exaggeration

Josesph Dummit’s article spoke about the advertising and dialogue used by pharmaceutical companies and how this leads to consumers believing that they might have depression, high cholesterol, etc, even when they do not. While I thought that Dummit raised some … Continue reading

Posted in Uncategorized | Leave a comment

Week 7 – Summary

Having worked within the pharmaceutical sector for more than a decade, Matheson writes from the perspective of an industry insider.  Matheson’s article “Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry” can be taken as … Continue reading

Aside | Posted on by | Leave a comment

Accepting the Side Effects of Separating Research and Industry

Sismondo suggests that a total severing of the relationships between the pharmaceutical industry and medical research is the most complete solution to the problem of bias within the system of research, trials and publication on drugs. Such a separation between … Continue reading

Posted in Uncategorized | Leave a comment

Talking Points Concerning Nationalization of Pharmaceutical Research

At the end of his paper, Sismondo suggests nationalizing clinical trial planning and funding in order to avoid the issues which come about as a result of industry funded research. I think this is an interesting suggestion and opens up … Continue reading

Posted in Uncategorized | Leave a comment

Policy as synonymous with “solution”

I often experience a certain amount of pessimistic skepticism when I encounter discussions that posit the development of policy as a solution to a particular ill.  In this case, I refer specifically to the section entitled “An International Standard of … Continue reading

Posted in Uncategorized | Leave a comment

Business as usual…

In his article, Ghosts in the Machine: Publication Planning in the Medical Sciences, Sismondo attempts to explore the relationship of publication planners to the pharmaceutical industry. Their job is to assist pharmaceutical companies in their research and most importantly: the … Continue reading

Posted in Uncategorized | Leave a comment

When the Evaluated Pay their Evaluators…

                The recent financial meltdown revealed large bond ratings agencies, notably Moody’s, Finch and S&P, would rate “toxic bonds” as “prime”. To clarify, certain profit-seeking companies are paid to rate bonds (kinds of … Continue reading

Posted in Uncategorized | 1 Comment